

WFNOS 2017

Final Programme

MAY 4 - 7, 2017
5TH QUADRENNIAL MEETING
ZURICH, SWITZERLAND




www.wfnos.com

**World Federation of
Neuro-Oncology Societies**


Kongresshaus Zürich
Zurich, Switzerland

FLOORPLANS

GROUND FLOOR



FIRST FLOOR



EVENT	ROOM	FLOOR
Educational Day:	Kongresssaal	First Floor
	Gartensaal	Ground Floor
Nurse Session:	Vortragssaal	First Floor
WFNOS Meeting - Lecture Halls:	Kongresssaal	First Floor
	Kammermusiksaal	First Floor
	Gartensaal	Ground Floor
Preview Centre:	Tagungszentrum 1	Ground Floor
Side Meetings:	Tagungszentrum 2	Ground Floor
	Tagungszentrum 3	Ground Floor
Board Room:	Seezimmer 2	First Floor
Poster Area:		First Floor
Exhibition & Catering Area:	Panoramasaal	First Floor

TABLE OF CONTENTS



GENERAL

Welcoming Address	2
Committees – Board – Organisation	3
Accreditation & Future Meetings	4

SCIENTIFIC PROGRAMME

Programme at a Glance	6
---------------------------------	---

Detailed Scientific Programme

WFNOS - EORTC Educational Day

Thursday, May 4	8
---------------------------	---

Nurse Session

Friday, May 5.	10
------------------------	----

WFNOS Meeting

Friday, May 5.	11
Saturday, May 6.	16
Sunday, May 7.	20

Side Meetings	21
-------------------------	----

SCIENTIFIC INFORMATION

Oral Presentations	24
Poster Viewing	26
Poster Topics	27

CORPORATE SYMPOSIA

Corporate Symposium 1	30
Corporate Symposium 2	30
Corporate Symposium 3	31
Corporate Symposium 4	31
Corporate Symposium 5	32
Corporate Symposium 6	32

INFORMATION

Networking Events	37
General Information	39
Registration Fees	47
Sponsor & Exhibitor Listing	53



WELCOMING ADDRESS



DEAR COLLEAGUES, DEAR FRIENDS,

The European Association of Neuro-Oncology (EANO) is honoured to host the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) from May 4-7, 2017 and invites you to join this outstanding event for Neuro-Oncology worldwide.

Knowledge and interest in Neuro-Oncology have grown tremendously and globalization has reached Neuro-Oncology, too.



Owing to joined efforts of EANO, the US Society for Neuro-Oncology (SNO), the Asian Society for Neuro-Oncology (ASNO) and an increasing number of National Neuro-Oncology societies, WFNOS has become an active umbrella organization seeking to promote Neuro-Oncology in all aspects of care and research, and everywhere across the globe.

Thus, WFNOS 2017 will provide an opportunity to share up-to-date advances in basic science, translational and clinical research in a multidisciplinary setting.



Zurich is an attractive city that offers something for everyone: culture, nature, indulgence and an excellent infrastructure. It is situated in the heart of Switzerland as a getaway to the Alps, as well in the very centre of Europe with direct flight connections to most major airports worldwide.

We wish you a pleasant time at the WFNOS 2017 Quadrennial Meeting in Zurich/Switzerland.

Best regards,



Michael Weller
President
WFNOS 2017

Ryo Nishikawa
Co-Chair
ASNO

David Reardon
Co-Chair
SNO

Patrick Roth
Local Coordinator
WFNOS 2017



COMMITTEES – BOARD – ORGANISATION

<p>WFNOS 2017 Scientific Committee</p> <p>Congress President Michael Weller (CH)</p> <p>Local Coordinator Patrick Roth (CH)</p> <p>Co-Chairs Ryo Nishikawa (JP) David Reardon (US)</p> <p>Representatives EANO Roger Henriksson (SE) Riccardo Soffietti (IT) Wolfgang Wick (DE)</p> <p>Representatives ASNO Zhong-Ping Chen (CN) Yuchi Hirose (JP) Kim Se-Hyuk (KR)</p> <p>Representatives SNO Kenneth Aldape (US) Susan Chang (US) Antonio Chiocca (US)</p> <p>Representatives WFNOS Member Societies Ufuk Abacioglu (TR) Carmen Balaña Quintero (ES) Carmine M. Carapella (IT) Steven De Vleeschouwer (BE) Didier Frappaz (FR) Thomas Hundsberger (CH) Khaled Abdel Karim (EG) Marcos Maldaun (BR) Josef Pichler (AT) Jalali Rakesh (IN) Uwe Schlegel (DE) Susan Short (UK) Takashi Tamiya (JP) Martin van den Bent (NL)</p>	<p>Educational Day Organising Committee</p> <p>Representatives EORTC Pim French (NL) Emilie Le Rhun (FR)</p> <p>Representatives EANO Simone Niclou (LU) Patrick Roth (CH)</p> <p>EANO Executive Board President: Wolfgang Wick (DE) Past President: Michael Weller (CH) Treasurer: Geoffrey Pilkington (UK)</p> <p>EANO Board Members Elisabeth Cohen-Jonathan Moyal (FR) Roger Henriksson (SE) Matthias Preusser (AT) Guido Reifenberger (DE) Robert Ruda (IT) Martin van den Bent (NL) Colin Watts (UK)</p> <p>Nurse Board Member Ingela Oberg (UK)</p>
<p>Exhibition and Advertisements Medizinische Ausstellungs- und Werbegesellschaft MAW Freyung 6 1010 Vienna, Austria T: +43 1 53663-87 F: +43 1 5356016 E: maw@media.co.at</p>	<p>WFNOS 2017 Conference Secretariat c/o WMA Kongress GmbH Ms. Anja Rosenkranz Alser Strasse 4 1090 Vienna, Austria T: +43 1 405 13 83-27 F: +43 1 407 82 74 E: wfnos2017@medacad.org</p> <div data-bbox="1281 1178 1485 1368" data-label="Image"> </div> <div data-bbox="1209 1559 1481 1724" data-label="Image"> </div>
<p>Accommodation Zurich Tourist Service At the Main Railway Station 8001 Zurich, Switzerland T: +41 44 215 40 00 F: +41 44 215 40 44 E: touristservice@zuerich.com www.zuerich.com</p>	<p>Venue of WFNOS 2017 Kongresshaus Zürich main entrance: Claridenstrasse 5 8002 Zurich, Switzerland T: +41 44 206 36 36 www.kongresshaus.ch</p>



ACCREDITATION & FUTURE MEETINGS

CME CREDITS

The 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.



The 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) is designated for a maximum of (or 'for up to') **20 hours of European external CME credits**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The rules of the EACCME state that participants are kindly asked to give feedback (online evaluation after the meeting).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

EONS APPROVAL

Nurse Session:

Please note that the Nurse Session on Friday, May 5, 2017 from 09:00-17:00 hrs has been endorsed by EONS.



FUTURE CONFERENCES



- | | |
|------------------|--|
| EANO 2018 | October 11-14, 2018 Stockholm Waterfront Congress Centre, Stockholm (SWEDEN) |
| EANO 2019 | September 19-22, 2019 Centre de Congrès, Lyon (FRANCE) |
| EANO 2020 | September 10-13, 2020 Scottish Event Campus, Glasgow (UNITED KINGDOM) |

More information will be available online at www.eano.eu closer to the conferences.

SCIENTIFIC PROGRAMME



Programme at a Glance 6

Detailed Scientific Programme

WFNOS - EORTC Educational Day

Thursday, May 4 8

Nurse Session

Friday, May 5. 10

WFNOS Meeting

Friday, May 5. 11

Saturday, May 6. 16

Sunday, May 7. 20

Side Meetings 21





PROGRAMME AT A GLANCE

	Thursday, May 4		Friday, May 5			
	EDUCATIONAL DAY					
Room	Kongresssaal (CLINICAL TRACK)	Gartensaal (BASIC SCIENCE TR.)	Kongresssaal	Gartensaal	Kammermusiksaal	Vortragssaal (NURSE SESSION)
Level	First Floor	Ground Floor	First Floor	Ground Floor	First Floor	First Floor
07:00 – 07:15						
07:15 – 07:30						
07:30 – 07:45						
07:45 – 08:00						
08:00 – 08:15						
08:15 – 08:30			Meet the Expert Session 1 Immuno-oncology	Meet the Expert Session 2 Health-related quality of life and other patient-centered outcomes in clinical practice	Meet the Expert Session 3 Advances in neurosurgery	
08:30 – 08:45						
08:45 – 09:00						
09:00 – 09:15	Clinical updates	Tumor genetics 2.0				Welcome and Introduction
09:15 – 09:30						Imaging-(radiological pres.)
09:30 – 09:45			Oral Session 1 Glioblastoma	Oral Session 2 Pediatric tumors	Oral Session 3 Brain metastasis	Brain metastases management guidelines: Surgery
09:45 – 10:00						Chall. in the design and conduct of clin.trials for patients with brain met.
10:00 – 10:15						
10:15 – 10:30						
10:30 – 10:45	Coffee Break	Coffee Break	Coffee Break			
10:45 – 11:00						
11:00 – 11:15	Neurocutaneous syndromes	Metabolic abnormalities and therapeutic potential				The role of the BBB for targeted therapies of brain metastases
11:15 – 11:30			Oral Session 4 Neurosurgery and neuroimaging	Oral Session 5 Quality of life, palliative care and neurotoxicity	Oral Session 6 Molecular and cell biology	RT treatments f. brain metastases
11:30 – 11:45						Neoplastic Meningitis
11:45 – 12:00						Tolerance of normal brain to treatments
12:00 – 12:15						
12:15 – 12:30						
12:30 – 12:45	Lunch Break	Lunch Break	Corporate Lunch Symposium 2	Lunch Break		
12:45 – 13:00						
13:00 – 13:15						
13:15 – 13:30						
13:30 – 13:45	Management of gliomas	Tumor microenvironment				Recent developments in the management of brain metastases
13:45 – 14:00						
14:00 – 14:15			Opening & Presidential Ad.			
14:15 – 14:30			Keynote Lecture EANO			Evolution of management of brain metastases
14:30 – 14:45						
14:45 – 15:00						
15:00 – 15:15	Coffee Break	Coffee Break				Closing Remarks
15:15 – 15:30						
15:30 – 15:45	Research in neuro-oncology	Tumor biology	Plenary Session 1 Brain metastasis: the commonest primaries	Plenary Session 2 Lower grade gliomas	Plenary Session 3 Pediatric brain tumors: current cooperative group trials	
15:45 – 16:00						
16:00 – 16:15						
16:15 – 16:30						
16:30 – 16:45						
16:45 – 17:00		Corporate Symposium 1				
17:00 – 17:15						
17:15 – 17:30						
17:30 – 17:45						
17:45 – 18:00						
18:00 – 18:15						
18:15 – 18:30						
18:30 – 18:45						
18:45 – 19:00			Corporate Symposium 3			
19:00 – 19:15						
19:15 – 19:30						
19:30 – 19:45	Networking Event					
19:45 – 20:00						
20:00 – 20:15						
20:15 – 20:30						
20:30 – 20:45						
20:45 – 21:00						
21:00 – 21:15						
21:15 – 21:30						



Saturday, May 6			Sunday, May 7	
Kongresssaal	Gartensaal	Kammermusiksaal	Kongresssaal	Room
First Floor	Ground Floor	First Floor	First Floor	Level
				07:00 – 07:15
				07:15 – 07:30
				07:30 – 07:45
				07:45 – 08:00
Meet the Experts Session 4 Sympotomatic tratments for brain tumor patients	Meet the Experts Session 5 Neuroimaging across brain tumor entities	Meet the Experts Session 6 Radiation biology & radiotherapy	WFNOS Session	08:00 – 08:15
				08:15 – 08:30
				08:30 – 08:45
				08:45 – 09:00
Keynote Lecture ASNO				09:00 – 09:15
				09:15 – 09:30
			EANO General Assembly	09:30 – 09:45
				09:45 – 10:00
Coffee Break			Oral Session 10 Abstract highlights	10:00 – 10:15
				10:15 – 10:30
				10:30 – 10:45
				10:45 – 11:00
Oral Session 7 Glioblastoma clinical	Oral Session 8 Meningiomas, schwannomas and lymphomas	Oral Session 9 Immunology	Coffee Break	11:00 – 11:15
				11:15 – 11:30
				11:30 – 11:45
			Oral Session 11 Gliomas	11:45 – 12:00
				12:00 – 12:15
Corporate Lunch Symposium 4			Keynote Lecture SNO	12:15 – 12:30
				12:30 – 12:45
				12:45 – 13:00
				13:00 – 13:15
			Poster Awards & Closing remarks – From President to President	13:15 – 13:30
				13:30 – 13:45
				13:45 – 14:00
				14:00 – 14:15
Plenary Session 4 Glioblastoma	Plenary Session 5 Leptomeningeal metastasis	Plenary Session 6 Meningioma		14:15 – 14:30
				14:30 – 14:45
				14:45 – 15:00
				15:00 – 15:15
Corporate Symposium 5				15:15 – 15:30
				15:30 – 15:45
				15:45 – 16:00
				16:00 – 16:15
				16:15 – 16:30
Corporate Symposium 6				16:30 – 16:45
				16:45 – 17:00
				17:00 – 17:15
				17:15 – 17:30
				17:30 – 17:45
				17:45 – 18:00
				18:00 – 18:15
				18:15 – 18:30
				18:30 – 18:45
				18:45 – 19:00
				19:00 – 19:15
				19:15 – 19:30
				19:30 – 19:45
				19:45 – 20:00
				20:00 – 20:15
				20:15 – 20:30
				20:30 – 20:45
				20:45 – 21:00
				21:00 – 21:15
				21:15 – 21:30
WFNOS Evening "Uto Kulm"				



THURSDAY, MAY 4

WFNOS - EORTC EDUCATIONAL DAY

Thursday, May 4

CLINICAL TRACK

Room: Kongresssaal

09:00 – 10:30	Clinical Updates <i>Chairs: Emilie Le Rhun, Lille/FR; Patrick Roth, Zurich/CH</i>
09:00 – 09:30	The new WHO classification for clinicians; <i>Andreas von Deimling, Heidelberg/DE</i>
09:30 – 10:00	Rare primary brain tumors: how I do it
10:00 – 10:30	Primary CNS lymphoma; <i>Khe Hoang-Xuan, Paris/FR</i>
	Ependymoma; <i>Mark R. Gilbert, Bethesda/US</i>
<i>10:30 – 11:00</i>	<i>Coffee Break</i>
11:00 – 12:30	Neurocutaneous syndromes <i>Chairs: Emilie Le Rhun, Lille/FR; Patrick Roth, Zurich/CH</i>
11:00 – 11:30	Von Hippel-Lindau disease; <i>Tracy Todd Batchelor, Boston/US</i>
11:30 – 12:00	Neurofibromatosis; <i>Marcos Tatagiba, Tuebingen/DE</i>
12:00 – 12:30	Tuberous sclerosis; <i>Daniel Cahill, Boston/US</i>
<i>12:30 – 13:30</i>	<i>Lunch Break</i>
13:30 – 15:00	Management of gliomas <i>Chairs: Frederic Dhermain, Villejuif/FR; Jacob C. Reijneveld, Amsterdam/NL</i>
13:30 – 14:00	Report from the jumpstarting brain tumor drug development coalition imaging standardization steering committee; <i>Timothy Cloughesy, Los Angeles/US</i>
14:00 – 14:30	Supramaximal resection of low-grade gliomas?; <i>Hugues Duffau, Montpellier/FR</i>
14:30 – 15:00	Conservative management of lower-grade gliomas; <i>Warren Mason, Toronto/CA</i>
<i>15:00 – 15:30</i>	<i>Coffee Break</i>
15:30 – 16:30	Research in neuro-oncology <i>Chairs: Frederic Dhermain, Villejuif/FR; Jacob C. Reijneveld, Amsterdam/NL</i>
15:30 – 16:00	How do I write a scientific paper or a grant proposal?; <i>Deborah Blumenthal, Tel Aviv/IL</i>
16:00 – 16:30	Challenges in the conduct of academic clinical trials: a global view; <i>Roger Stupp, Chicago/US</i>
16:45 – 18:15	Corporate Symposium Room: Gartensaal <i>see page 30</i>






THURSDAY, MAY 4

BASIC SCIENCE TRACK

Room: Gartensaal

09:00 – 10:30 Tumor genetics 2.0*Chairs: Pim French, Rotterdam/NL; Simone Niclou, Luxembourg/LU*09:00 – 09:30 Liquid biopsies; *Tom Wurdinger, Amsterdam/NL*09:30 – 10:00 Single cell sequencing of gliomas; *Mario Suva, Boston/US*10:00 – 10:30 Fusion genes in gliomas; *Antonio Iavarone, New York/US*10:30 – 11:00 *Coffee Break***11:00 – 12:30 Metabolic abnormalities and therapeutic potential***Chairs: Pim French, Rotterdam/NL; Simone Niclou, Luxembourg/LU*11:00 – 11:30 Glutamine GBM metabolism; *Saverio Tardito, Glasgow/UK*11:30 – 12:00 Development and properties of a novel pan IDH1 inhibitor; *Stephan Pusch, Heidelberg/DE*12:00 – 12:30 Exploring metabolic vulnerabilities in IDH mutant gliomas; *Simone Niclou, Luxembourg/LU*12:30 – 13:30 *Lunch Break***13:30 – 15:00 Tumor microenvironment***Chairs: Rolf Bjerkvig, Bergen/NO; Geoffrey Pilkington, Portsmouth/UK*13:30 – 14:00 Immunotherapy; *Christel Herold-Mende, Heidelberg/DE*14:00 – 14:30 Microglia; *Bozena Kaminska, Warsaw/PL*14:30 – 15:00 Scientific and clinical overview on TTF; *Patrick Roth, Zurich/CH*15:00 – 15:30 *Coffee Break***15:30 – 16:30 Tumour biology***Chairs: Rolf Bjerkvig, Bergen/NO; Geoffrey Pilkington, Portsmouth/UK*15:30 – 16:00 Rethinking EGFR; *Hui Gan, Melbourne/AU*16:00 – 16:30 Tumour evolution; *Roel Verhaak, Houston/US***16:45 – 18:15 Corporate Symposium**

Room: Gartensaal

see page 30



FRIDAY, MAY 5

NURSE SESSION

Friday, May 5

Room: Vortragssaal

Chair: Ingela Oberg, Cambridge/UK

- 09:00– 09:10** **Welcome & Introduction**
Ingela Oberg, Cambridge/UK
- 09:10 – 09:35** **Imaging (radiological presentation)**
David Summers, Edinburgh/UK
- 09:35 – 10:00** **Brain metastases management guidelines: Surgery**
Philippe Metellus, Marseille/FR
- 10:00 – 10:30** **Challenges in the design and conduct of clinical trials for patients with brain metastases**
Michael Weller, Zurich/CH
- 10:30 – 11:00* *Coffee Break*
- 11:00 – 11:20** **The role of the BBB for targeted therapies of brain metastases**
Matthias Preusser, Vienna/AT
- 11:20 – 11:40** **RT treatments for brain metastases (SRS/Gamma knife/Cyber knife)**
Fabio Iwamoto, New York/US
- 11:40 – 12:00** **Neoplastic meningitis**
Emilie Le Rhun, Lille/FR
- 12:00 – 12:30** **Tolerance of normal brain to treatments**
Riccardo Soffietti, Turin/IT
- 12:30 – 14:00* *Lunch Break / Corporate Lunch Symposium (Room: Kongresssaal)*
- 14:00 – 14:30** **Recent developments in the management of brain metastases**
Richard Baird, Cambridge/UK
- 14:30 – 15:15** **Evolution of management of brain metastases**
Liz Molloy, Manchester/UK
- 15:15– 15:30** **Closing remarks**
Ingela Oberg, Cambridge/UK
- 15:30 – 17:00** **WFNOS Meeting: Plenary Session 1 - Brain metastases: the commonest primaries**
(Room Kongresssaal)





FRIDAY, MAY 5



WFNOS MEETING

Friday, May 5

- 08:00 – 09:00** **Meet the Expert Session 1 – Immuno-oncology**
Room: Kongresssaal
Chairs: Michael Lim, Baltimore/US; Uwe Schlegel, Bochum/DE
- 08:00 – 08:20 iRANO
Hideho Okada, San Francisco/US
- 08:20 – 08:40 Biomarkers for predicting benefit from immuno-therapy
Matthias Preusser, Vienna/AT
- 08:40 – 09:00 Novel side effects and their management
Antonio Omuro, New York/US
- 08:00 – 09:00** **Meet the Expert Session 2 – Health-related quality of life and other patient-centered outcomes in clinical practice**
Room: Gartensaal
Chairs: Terri S. Armstrong, Houston/US; Sith Sathornsumetee, Bangkok/TH
- 08:00 – 08:20 Treatment of elderly glioblastoma patients: quantity of quality of survival?
Martin Taphoorn, The Hague/NL
- 08:20 – 08:40 Cognitive deterioration in patients with brain metastases: due to tumor or to treatment?
Jeffrey S. Wefel, Houston/US
- 08:40 – 09:00 Long-term survivors in neuro-oncology: how do they function?
Rakesh Jalali, Mumbai/IN
- 08:00 – 09:00** **Meet the Expert Session 3 – Advances in neurosurgery**
Room: Kammermusiksaal
Chairs: Carmine Carapella, Rome/IT; Colin Watts, Cambridge/UK
- 08:00 – 08:20 Extent of resection
Mitchel S. Berger, San Francisco/US
- 08:20 – 08:40 Local therapy
Manfred Westphal, Hamburg/DE
- 08:40 – 09:00 Neurosurgical implementation of tumor evolution and heterogeneity in glioblastoma
Do-Hyun Nam, Seoul/KR
- 09:15 – 10:30** **Oral Session 1: Glioblastoma**
Room: Kongresssaal
Chairs: Kenneth Aldape, Toronto/CA; John de Groot, Houston/US
- 09:15 – 09:25 Identification of the pre-malignant cell of origin in human glioblastoma multiforme
Mitra Siddhartha, Stanford/US
- 09:25 – 09:35 Human glioblastoma arises from normal subventricular zone harboring tumor-initiating mutations
Seok-Gu Kang, Seoul/KR
- 09:35 – 09:45 mtTERT promoter as a target for treatment of glioblastoma
Harshil Dhruv, Phoenix/US
- 09:45 – 09:55 Induction of differential macrophage and microglial glioblastoma phagocytosis by anti CD47 treatment - implication of tumor subtypes
Gregor Hutter, Stanford/US
- 09:55 – 10:05 Development of TERT-targeting therapy using eribulin mesylate in mouse glioblastoma model
Masamichi Takahashi, Tokyo/JP
- 10:05 – 10:15 Glioblastoma in the era of bevacizumab: an epidemiological study in the canton of Zurich, Switzerland
Dorothee Gramatzki, Zurich/CH
- 10:15 – 10:25 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
Erica Bell, Columbus/US



FRIDAY, MAY 5

09:15 – 10:30 Oral Session 2: Pediatric tumors

Room: Gartensaal

Chairs: Jonathan Finlay, Columbus/US; Michael Grotzer, Zurich/CH

- 09:15 – 09:25 Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma - the NOA-07 trial
Peter Hau, Regensburg/DE
- 09:25 – 09:35 Functional investigation of recurrent genetic aberrations in newly identified pediatric brain tumor entities
Sjoerd van Rijn, Heidelberg/DE
- 09:35 – 09:45 Need for reclassifying treatment strategies for different subgroups of SHH medulloblastoma, paediatric and adult SHH-MB fail differentially
Archya Dasgupta, Mumbai/IN
- 09:45 – 09:55 Long-term Outcome of infants and young children with newly diagnosed nodular desmoplastic medulloblastoma treated on “Head Start” III Protocol
Girish Dhall, Los Angeles/US
- 09:55 – 10:05 Prolonged survival of patients with recurrent medulloblastoma and atypical teratoid rhabdoid tumor treated with an antiangiogenic metronomic combination therapy
Irene Slavic, Vienna/AT
- 10:05 – 10:15 Risk factors for hypersomnia and narcolepsy and response to therapy in survivors of childhood brain tumors
Raja Khan, Memphis/US
- 10:15 – 10:25 Dose constraint model to predict neuroendocrine dysfunction in young patients with brain tumours- data from a prospective study of stereotactic conformal radiotherapy
Madan Maitre, Mumbai/IN

09:15 – 10:30 Oral Session 3: Brain metastasis


Room: Kammermusiksaal

Chairs: Khaled Abdel Karim, Cairo/EG; Frank Winkler, Heidelberg/DE

- 09:15 – 09:25 The role of the immune system in facilitating the formation of brain metastasis of breast cancer
Dana Mustafa, Rotterdam/NL
- 09:25 – 09:35 CSF metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients having high risk for leptomeningeal metastasis from brain metastasis or brain tumors
Ho-Shin Gwak, Goyang/KR
- 09:35 – 09:45 Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis
Adrienne Boire, New York/US
- 09:45 – 09:55 Gammaknife versus Linac based (EDGE) radiosurgery (SRS) for patients with limited brain metastases (BMS) from different solid tumor: a phase III randomized trial
Pierina Navarria, Rozzano/IT
- 09:55 – 10:05 Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Elena Pentsova, New York/US
- 10:05 – 10:15 Inadvertent underdosing of patients with neoplastic meningitis
Ayesha Ali, Hummelstown/US
- 10:15 – 10:25 Does improved intracranial control from whole brain radiation therapy translate to improved overall survival in patients with limited competing risk from systemic disease? A secondary analysis of EORTC 22952-26001
Stephanie Weiss, Philadelphia/US
- 10:30 – 11:00 Coffee Break

FRIDAY, MAY 5

- 11:00 – 12:15** **Oral Session 4: Neurosurgery and neuroimaging**
Room: Kongresssaal
Chairs: Alexander Lossos, Jerusalem/IL; Luca Regli, Zurich/CH
- 11:00 – 11:10 Survival benefit associated with Gross Total Resection (GTR) in oligodendrogliomas and astrocytomas: a Surveillance, Epidemiology, and End Results Program (SEER) based analysis
Clark Chen, La Jolla/US
- 11:10 – 11:20 First in human study of the Cleveland Multiport Catheter and convection enhanced delivery of topotecan and gadolinium for recurrent GBM: Updated results
Michael Vogelbaum, Cleveland/US
- 11:20 – 11:30 Extent of resection and overall survival in risk adjusted and exact matched analyses of 22,928 glioblastoma (all molecular subtypes) patients
Timothy Smith, Boston/US
- 11:30 – 11:40 Supratotal resection in newly diagnosed glioblastoma: role of this surgical strategy beyond contrast enhancing boundaries
Federico Pessina, Rozzano/IT
- 11:40 – 11:50 Radiomics features can characterize the glioblastoma progression on preoperative multimodal MRI
Jiun-Lin Yan, Cambridge/UK
- 11:50 – 12:00 DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy
Yoshie Umemura, New York/US
- 12:00 – 12:10 Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent glioma
Raymond Huang, Brookline/US
- 11:00 – 12:15** **Oral Session 5: Quality of life, palliative care and neurotoxicity**
Room: Gartensaal
Chairs: Thomas Hundtberger, St. Gallen/CH; Lakshmi Nayak, Boston/US
- 11:00 – 11:10 The D-2-hydroxyglutarate product of mutant IDH1 induces synchronized neuronal firing via NMDA receptor activation
Craig Horbinski, Chicago/US
- 11:10 – 11:20 Burnout and career satisfaction among neuro-oncology health care providers: an international survey
Shlomit Yust-Katz, Petach-Tikva/IL
- 11:20 – 11:30 Digital phenotyping: a novel method for quality of life assessment in patients with brain tumors
Timothy Smith, Boston/US
- 11:30 – 11:40 Optimizing the assessment of psychosocial support and unmet needs in glioma patients and their caregivers in clinical practice - First results of the observational prospective "ERASMUS" Study
Mirjam Renovanz, Mainz/DE
- 11:40 – 11:50 Palliative care in brain tumors: 15 years of activity of a Neuroncological Home Care Service
Andrea Pace, Rome/IT
- 11:50 – 12:00 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with glioblastoma treated on NRG Oncology's RTOG 0825
Terri Armstrong, Bethesda/US
- 12:00 – 12:10 Seizures in grade III gliomas: natural history and response to treatments
Roberta Rudà, Turin/IT







FRIDAY, MAY 5

- 11:00 – 12:15** **Oral Session 6: Molecular and cell biology**
Room: Kammermusiksaal
Chairs: Rolf Bjerkvig, Bergen/NO; Susan Short, Leeds/UK
- 11:00 – 11:10 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Ben Kinnersley, Surrey/UK
- 11:10 – 11:20 Combination RNAi therapy against glioma stem cells via sustained lipopolymeric nanoparticle delivery delays tumor progression
Dou Yu, Chicago/US
- 11:20 – 11:30 Characterisation of human brain tumour initiating cells leading invasion
Peter Hau, Regensburg/DE
- 11:30 – 11:40 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor
Priscilla Brastianos, Boston/US
- 11:40 – 11:50 YAP is essential for glioblastoma proliferation and survival in vitro and in vivo
Andrew Gogos, Melbourne/AU
- 11:50 – 12:00 Optimized radiotherapy protocols delay the malignant transformation of low-grade gliomas in-silico
Araceli Henares-Molina, Ciudad Real/ES
- 12:00 – 12:10 PI-3Ky inhibition suppresses glioblastoma tumorigenicity through disruption of an IL11-STAT3-MYC signaling axis between microglia and glioblastoma
Clark Chen, La Jolla/US
- 12:30 – 14:00** **Corporate Lunch Symposium**
Room: Kongresssaal
see page 30
- 12:30 – 14:00 *Lunch Break*
- 14:15 – 14:30** **Opening and Presidential Address**
Room: Kongresssaal
Michael Weller, Zurich/CH
- 14:30 – 15:15** **Keynote Lecture 1 - EANO**
Room: Kongresssaal
Chair: Marc Sanson, Paris/FR
 Current concepts and challenges of trial design in brain and leptomeningeal metastasis
Riccardo Soffietti, Turin/IT
- 15:30 – 17:00** **Plenary Session 1 - Brain metastasis: the commonest primaries**
Room: Kongresssaal
Chairs: Ufuk Abacioglu, Istanbul/TR; Christine Marosi, Vienna/AT
- 15:30 – 16:00 Lung cancer
Rolf Stahel, Zurich/CH
- 16:00 – 16:30 Breast cancer
Manmeet Ahluwalia, Cleveland/US
- 16:30 – 17:00 Malignant melanoma
Mark Rosenthal, Melbourne/AU



FRIDAY, MAY 5

- 15:30 – 17:00** **Plenary Session 2 – Lower grade gliomas**
Room: Gartensaal
Chairs: Jeremy Rich, Cleveland/US; Roger Stupp, Chicago/US
- 15:30 – 16:00 Clinical impact of the new WHO classification
Guido Reifenberger, Duesseldorf/DE
- 16:00 – 16:30 Current standards of care
Jan Buckner, Rochester/US
- 16:30 – 17:00 Current trials: a global perspective
Martin van den Bent, Rotterdam/NL
- 15:30 – 17:00** **Plenary Session 3 - Pediatric brain tumors: current cooperative group trials**
Room: Kammermusiksaal
Chairs: Stefan Pfister, Heidelberg/DE; Tai-Tong Wong, Taipei/TW
- 15:30 – 16:00 Europe
Didier Frappaz, Lyon/FR
- 16:00 – 16:30 United States of America
Roger J. Packer, Washington/US
- 16:30 – 17:00 Asia
Ryo Nishikawa, Saitama/JP
- 17:00 – 18:00** **Poster Session I with authors – P01.01 - P09.28 with wine and cheese**
- 18:15 – 19:45** **Corporate Symposium**
Room: Kongresssaal
see page 31





SATURDAY, MAY 6

Saturday, May 6

08:00 – 09:00 **Meet the Expert Session 4 – Symptomatic treatments for brain tumor patients** **Room: Kongresssaal**

Chairs: Alba Brandes, Bologna/IT; Andrew B. Lassman, New York/US

08:00 – 08:20 RANO guideline on steroid use and beyond
Patrick Wen, Boston/US

08:20 – 08:40 Epilepsy
Roberta Rudà, Turin/IT

08:40 – 09:00 Vascular disorders
James Perry, Toronto/CA

08:00 – 09:00 **Meet the Expert Session 5 – Neuroimaging across brain tumor entities** **Room: Gartensaal**

Chairs: Takashi Tamiya, Kagawa/Jp; Michael Vogelbaum, Cleveland/US

08:00 – 08:20 RANO: an update
Susan Chang, San Francisco/US

08:20 – 08:40 New MRI techniques
Martha Nowosielski, Heidelberg/DE

08:40 – 09:00 PET
Jörg-Christian Tonn, Munich/DE

08:00 – 09:00 **Meet the Expert Session 6 – Radiation biology & radiotherapy** **Room: Kammermusiksaal**

Chairs: Nicolaus Andratschke, Zurich/CH; Anthony Chalmers, Glasgow/UK



08:00 – 08:20 Pharmacological radiosensitization of tumor cells
Erik P. Sulman, Houston/US

08:20 – 08:40 Pharmacological radioprotection of nervous tissue
Normand J. Laperriere, Toronto/CA

08:40 – 09:00 High precision, high dose radiotherapy: hype or hope
Do Hoon Lim, Seoul/KR

09:15 – 10:00 **Keynote Lecture 2 - ASNO** **Room: Kongresssaal** *Chair: Monika Hegi, Lausanne/CH* hTERT in glioma - a multifaceted demigod *Koichi Ichimura, Tokyo/Jp*

10:00 – 10:30 *Coffee Break*





SATURDAY, MAY 6

10:30 – 12:00 Oral Session 7: Glioblastoma clinical**Room: Kongresssaal***Chairs: Manmeet Ahluwalia, Cleveland/US; Maria Carmen Balaña, Badalona/ES*

- 10:30 – 10:40 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status
Tobias Kessler, Heidelberg/DE
- 10:40 – 10:50 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial
Hans Wirsching, Zurich/CH
- 10:50 – 11:00 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143
Antonio Omuro, New York/US
- 11:00 – 11:10 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)
Martin van den Bent, Rotterdam/NL
- 11:10 – 11:20 Interim analysis data from Phase 2 study on efficacy, safety & intratumoral pharmacokinetics of oral Selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)
Andrew Lassman, New York/US
- 11:20 – 11:30 A combination of TERT and MGMT improves the prognostication of glioblastomas
Hideyuki Arita, Osaka/JP
- 11:30 – 11:40 Patterns of diagnostic marker assessment in adult diffuse glioma - a survey of the European Confederation of Neuropathological Societies
Adelheid Woehrer, Vienna/AT
- 11:40 – 11:50 Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT
Annette Molinaro, San Francisco/US
- 11:50 – 12:00 Standard of care temozolomide chemotherapy \pm tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial
Roger Stupp, Zurich/CH

10:30 – 12:00 Oral Session 8: Meningiomas, schwannomas and lymphomas**Room: Gartensaal***Chairs: Ulrich Herrlinger, Bonn/DE; Se-Hyuk Kim, Suwon/KR*

- 10:30 – 10:40 TERT promoter mutations in Meningiomas drive tumor aggressiveness and cellular immortalization
Sabine Spiegl-Kreinecker, Linz/AT
- 10:40 – 10:50 A novel set of patient-derived orthotopic xenograft (PDOX) models of primary and recurrent intracranial meningioma
Sarah Injac, Houston/US
- 10:50 – 11:00 Genomic landscape of meningiomas
Wenya Linda Bi, Boston/US
- 11:00 – 11:10 NF2 Disruption by genomic rearrangements drives a subset of radiation induced meningiomas
Suganth Suppiah, Markham/CA
- 11:10 – 11:20 Stereotactic radiosurgery for the treatment of meningiomas eligible for complete resection
Juman Tutunji, Cologne/DE
- 11:20 – 11:30 Fatigue in patients with surgically treated meningiomas
Sophie van der Linden, Tilburg/NL
- 11:30 – 11:40 The somatic landscape of Schwannoma
Gelareh Zadeh, Toronto/CA
- 11:40 – 11:50 A head-to-head comparison of two different high dose methotrexate (HDMTX) - and high dose cytarabine (HDArC)-based chemotherapy regimens in younger patients with primary central nervous system lymphoma (PCNSL)
Laura Rieger, Berlin/DE
- 11:50 – 12:00 Management of Primary Central Nervous System Lymphoma in Spain in the last decade: a case series of the Spanish Group of Neuro-Oncology and GELTAMO
Roser Velasco, Barcelona/ES




SATURDAY, MAY 6

10:30 – 12:00 Oral Session 9: Immunology

Room: Kammermusiksaal

Chairs: Antoine Carpentier, Paris/FR; Gaetano Finocchiaro, Milan/IT


- 10:30 – 10:40 Radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with lower grade glioma in the Cancer Genome Atlas (TCGA) Dataset
In Ah Kim, Seongnamsi/KR
- 10:40 – 10:50 Enhancing immunity while neutralizing T cell-induced immunosuppression through combinatorial immunotherapy of glioblastoma
Derek Wainwright, Chicago/US
- 10:50 – 11:00 Synergistic activity of NKG2D-based chimeric antigen receptor (CAR)-T cells and radiotherapy against glioma
Tobias Weiss, Zurich/CH
- 11:00 – 11:10 Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of H3.3.K27M-specific T-cell receptor for T-cell therapy in gliomas
Hideho Okada, San Francisco/US
- 11:10 – 11:20 Synergistic effect of reirradiation and PD-1 inhibitors in recurrent high-grade gliomas
Fabio Iwamoto, New York/US
- 11:20 – 11:30 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial
Manish Aghi, San Francisco/US
- 11:30 – 11:40 Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea
Doo-sik Kong, Seoul/KR
- 11:40 – 11:50 Randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma
Yoshihiro Muragaki, Tokyo/JP
- 11:50 – 12:00 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice
Lukas Bunse, Heidelberg/DE
- 12:15 – 13:15 Corporate Lunch Symposium**
Room: Kongresssaal
see page 31
- 12:15 – 13:15 Lunch Break





SATURDAY, MAY 6




- 13:30 – 15:00** **Plenary Session 4 - Glioblastoma**
Room: Kongresssaal
Chairs: Tracy Todd Batchelor, Boston/UK; Zhong-Ping Chen, Guangzhou/CN
- 13:30 – 14:00 IDH as a therapeutic target
Michael Platten, Heidelberg/DE
- 14:00 – 14:30 Vaccination strategies
Michael Weller, Zurich/CH
- 14:30 – 15:00 Viral therapy
John Sampson, Durham/US
- 13:30 – 15:00** **Plenary Session 5 – Leptomeningeal metastasis**
Room: Gartensaal
Chairs: Lisa De Angelis, New York/US; Roger Henriksson, Umea/SE
- 13:30 – 14:00 Identifying cancers of unknown origin from small samples and liquid biopsies
Pieter Wesseling, Amsterdam/NL
- 14:00 – 14:30 Biomarkers for the diagnosis and treatment of leptomeningeal metastases from solid cancers
Michael Glantz, Hershey/US
- 14:30 – 15:00 Challenges for standardization of diagnosis and treatment of leptomeningeal metastasis: an update on the LANO and EANO/ESMO efforts
Emilie Le Rhun, Lille/FR
- 13:30 – 15:00** **Plenary Session 6 – Meningioma**
Room: Kammermusiksaal
Chairs: Evanthia Galanis, Rochester/US; Roland Goldbrunner, Cologne/DE
- 13:30 – 14:00 Surgery
Gelareh Zadeh, Toronto/CA
- 14:00 – 14:30 Radiotherapy
Minesh Mehta, Baltimore/US
- 14:30 – 15:00 Systemic therapy
Priscilla Brastianos, Boston/US
- 15:15 – 16:15** **Corporate Symposium**
Room: Kongresssaal
see page 32
- 16:30 – 18:00** **Corporate Symposium**
Room: Kongresssaal
see page 32
- 18:00 – 19:00** **Poster Session II with authors – P09.29 - P19.05 with wine and cheese**





SUNDAY, MAY 7

Sunday, May 7

08:00 – 09:30	WFNOS session – Presentation by Charter Societies Room: Kongresssaal <i>Chairs: Yong-Kil Hong, Seoul/KR; Michael Weller, Zurich/CH</i>	
08:00 – 08:30	Molecular targeted therapy in glioblastoma <i>Wolfgang Wick, Heidelberg/DE</i>	
08:30 – 09:00	Local therapy in glioblastoma <i>E. Antonio Chiocca, Boston/US</i>	
09:00 – 09:30	Correlation between genetic subgrouping and chemotherapy sensitivity of gliomas <i>Yuchi Hirose, Toyooka/JP</i>	
09:30 – 10:00	EANO General Assembly Room: Kongresssaal	
10:00 – 11:00	Oral Session 10: Abstract Highlights Room: Kongresssaal <i>Chairs: Olivier Chinot, Marseille/FR; Marcos Maldaun, São Paulo/BR</i>	
10:00 – 10:15	Genomic landscape of pituitary adenomas <i>Wenya Linda Bi, Boston/US</i>	
10:15 – 10:30	R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas <i>Mirco Friedrich, Heidelberg/DE</i>	
10:30 – 10:45	Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 <i>David Reardon, Boston/US</i>	
11:00 – 11:30	Coffee Break	
11:30 – 12:30	Oral Session 11: Gliomas Room: Kongresssaal <i>Chairs: Evangelia Razis, Athens/GR; Josef Pichler, Linz/AT</i>	
11:30 – 11:42	Temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: a phase II AINO (Italian Association for Neuro-Oncology) study <i>Alessia Pellerino, Turin/IT</i>	
11:42 – 11:54	Risk-adjusted survival outcomes for and features of 1p/19q codeletion oligodendrogliomas <i>Timothy Smith, Boston/US</i>	
11:54 – 12:06	Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas <i>Shai Rosenberg, Jerusalem/IL</i>	
12:06 – 12:18	Adult IDH wild-type lower-grade gliomas should be further stratified <i>Ho Ng, Hong Kong/HK</i>	
12:18 – 12:30	ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma <i>Michael Weller, Zurich/CH</i>	
12:30 – 13:15	Keynote Lecture 3 – SNO Room: Kongresssaal <i>Chair: Pierre-Yves Dietrich, Geneva/IT</i> Immunotherapy: advances and future directions <i>David Reardon, Boston/US</i>	
13:15 – 14:00	Awards & Closing remarks – from President to President Room: Kongresssaal	



SIDE MEETINGS

As per date of printing.

Thursday, May 5, 2017

13:00 – 15:00	BTFC Steering Committee Meeting *	Tagungszentrum 2
15:30 – 16:30	WFNOS General Assembly *	Tagungszentrum 2

Friday, May 6, 2017

09:00 – 11:00	EORTC 1709 *	Tagungszentrum 2
11:00 – 12:00	EORTC/MGMT Task Force *	Tagungszentrum 3
12:30 – 14:00	EANO Board Meeting *	Tagungszentrum 2
14:15 – 15:30	GLASS Consortium *	Tagungszentrum 3
15:30 – 16:00	Press Meeting	Tagungszentrum 2
17:00 – 18:00	Meet the Sponsors Meeting *	Tagungszentrum 2
17:30 – 18:30	EORTC BTG CNC Metastasis Committee *	Tagungszentrum 3

Saturday, May 7, 2017

10:00 – 12:00	Medulloblastoma in adults: EORTC/NRG-Cooperation *	Tagungszentrum 2
15:30 – 17:00	EANO palliative care task force meeting *	Tagungszentrum 2
17:15 – 18:15	EORTC Meningioma Committee *	Tagungszentrum 2

* Closed Meeting





SCIENTIFIC INFORMATION



Oral Presentations	24
Poster Viewing	26
Poster Topics	27



ORAL PRESENTATIONS

PUBLICATION

Please note that your work will be published in the May issue of the journal “Neuro-Oncology”.

INFORMATION FOR ORAL PRESENTERS

The Preview Centre is located in the **Room Tagungszentrum 1**.

SPEAKING TIME

The chairpersons of your session will be strict in allowing no more than the time allotted to your presentation. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

Please **rehearse your talk** to make sure it will fit comfortably into the available time.

Please note that, as a rule, presenters can show a (final) slide with all **acknowledgements**, however, in view of the short time available, **names cannot be read to the audience**.

Please see the detailed programme for any time changes.

COMMERCIAL DISCLOSURE INFORMATION

Due to EACCME regulations, **authors are requested to disclose possible conflicts of interest on the first slide**.

A **conflict of interest** is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state “*I have no commercial disclosure*”.



ORAL PRESENTATIONS

PROJECTION AND TECHNICAL SETTING

PowerPoint is the only communication tool available in all session halls.

The Preview Centre is located in the **Room Tagungszentrum 1**.

1. Please note that only computers provided by the congress may be used for showing your presentations.
All PowerPoint presentations must be handed in at the Preview Centre.
2. All presentations are loaded into a PowerPoint handling system that will store and distribute your presentation to the session hall in time for your session.
3. All PowerPoint presentations should be handed in **at least 2 hours before the session starts**.
The opening hours of the Preview Centre are as follows:
Wednesday, May 3: 16:00 – 19:30 hrs
Thursday, May 4: 08:00 – 18:45 hrs
Friday, May 5: 07:30 – 20:00 hrs
Saturday, May 6: 07:30 – 18:30 hrs
Sunday, May 7: 07:30 – 14:00 hrs
4. Please check your presentation carefully on the Preview Room computer assigned by the staff before the final sign off.
5. The professional staff of the Preview Centre will load your presentation into the system so that it will be available on the computer in your session hall when you come to speak.
6. If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to their corresponding session halls at the time of your sessions.
7. The PowerPoint handling and distribution system is optimized for **MS PowerPoint (last version) and “*.pdf” (Adobe Acrobat)-files**. The uploading of „DVD-Movies“ is not supported.
8. The supported data media are: **CD, DVD (as Data-storage-medium) and USB-Memory Key**.
You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem.
All needed files (including the movie files!) - have to be saved on the data media.
Presentations can also be taken off speakers notebooks at the Preview Centre.
9. The fonts that are used in the presentations should be “Latin-based fonts“. If the speaker needs special fonts, they should be stored as “embedded fonts“ with the presentation (File -> save as “name of presentation“ and under “tools“ -> save options mark the checkbox “embed True type fonts“ and select “embed all characters“).
10. When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
11. As format for embedded movies “MPEG2 - movies“ are preferred (but can also be *.avi, *.wmv).
If Codecs are used, the Code package DIVx in the current version, which can be found under www.divx.com, should be chosen.
12. Presentations should be saved as “*.ppt“, “*.pptx” (= PowerPoint) or “*.pps“, *.ppsx“ (= PowerPoint Slideshow) - file and movies as separate files on the data media.
13. The computers and projectors will be set up and optimised for **1920 x 1080 resolution (ratio 16 : 9)**.

These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speaker's comfort.



POSTER VIEWING

INFORMATION FOR POSTER PRESENTERS

POSTER VIEWING / SESSIONS (Poster Area – Kongressfoyer)

Poster Session I (Poster Numbers P01.01-P09.28)	Friday, May 5, 17:00-18:00
Poster Session II (Poster Numbers P09.29-P19.05)	Saturday, May 6, 18:00-19:00

Schedule for display, mounting and removal

Friday, May 5, 17:00-18:00

Poster Session I (Poster Numbers P01.01-P09.28)

Poster mounting:

For those posters displayed in Poster Session I the poster mounting is possible on Friday, May 5, from 08:00-12:30 hrs. Posters within the Poster Session I will be on display on Friday, May 5 from 17:00-18:00 hrs.

Poster removal:

Friday, May 5 from 18:00-20:15 hrs.

Please note that posters not removed until May 5, 20:15 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Saturday, May 6, 18:00-19:00

Poster Session II (Poster Numbers P09.29-P19.05)

Poster mounting:

For those posters displayed in Poster Session II the poster mounting is possible on Saturday, May 6, from 08:00-12:15 hrs. Posters within the Poster Session II will be on display on Saturday, May 6 from 18:00-19:00 hrs.

Poster removal:

Saturday, May 6 from 19:00-19:45 hrs.

Please note that posters not removed until May 6, 19:45 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Poster Board Number

Poster authors should have received their poster board number by email. You can also find your poster board number in the abstract book. Please note that both poster numbers for both days will be shown on the poster board. First poster number is indicated for the poster on Friday, Poster Session I, and the second poster number is indicated for the poster on Saturday, Poster Session II.

Presence at Posters

Please note that the posters have been divided into two separate poster sessions. In order to enable discussion and interaction with other participants, it is mandatory for you or one of your group members to be present at your poster board during the according poster session.

Poster Format

The usable surface on the poster board is **90 cm width x 150 cm height** and posters should be in **portrait format**. Only adhesive tape can be used to mount posters. Material to mount the posters is provided.



POSTER TOPICS

POSTER TOPICS

P01	Molecular and cell biology	P01.01-37
P02	Epidemiology	P02.01-03
P03	Neuropathology	P03.01-25
P04	Neuroimaging.	P04.01-27
P05	Neurotoxicity and neuroprotection	P05.01-07
P06	Immunology and immunotherapy: experimental	P06.01-11
P07	Immunology and immunotherapy: clinical	P07.01-05
P08	Gliomas: experimental.	P08.01-69
P09a	Glioblastoma: clinical	P09.01-28
P09b	Glioblastoma: clinical	P09.29-63
P10	Other gliomas: clinical	P10.01-27
P11	Pediatric brain tumours.	P11.01-15
P12	Meningiomas	P12.01-26
P13	Brain and leptomeningeal metastases: experimental.	P13.01-04
P14	Brain and leptomeningeal metastases: clinical.	P14.01-25
P15	Primary central nervous system lymphoma (PCNSL).	P15.01-06
P16	Neurosurgery	P16.01-33
P17	Radiation oncology	P17.01-18
P18	Quality of life	P18.01-16
P19	Supportive and palliative care	P19.01-05

POSTER VIEWING

Poster Viewing 1:

Friday, May 5, 2017 from 17:00-18:00 hrs


P01	Molecular and cell biology
P02	Epidemiology
P03	Neuropathology
P04	Neuroimaging
P05	Neurotoxicity and neuroprotection
P06	Immunology and immunotherapy: experimental
P07	Immunology and immunotherapy: clinical
P08	Gliomas: experimental
P09a	Glioblastoma: clinical

Poster Viewing 2:

Saturday, May 6, 2017 from 18:00-19:00 hrs

P09b	Glioblastoma: clinical
P10	Other gliomas: clinical
P11	Pediatric brain tumours
P12	Meningiomas
P13	Brain and leptomeningeal metastases: experimental
P14	Brain and leptomeningeal metastases: clinical
P15	Primary central nervous system lymphoma (PCNSL)
P16	Neurosurgery
P17	Radiation oncology
P18	Quality of life
P19	Supportive and palliative care

**35% Special
Congress Discount**



Progressive Neuroblastoma

Innovation and Novel Therapeutic Strategies

Editors
Holger Christiansen
Nina Merete Christiansen

Vol. 20: Progressive Neuroblastoma
Innovation and Novel Therapeutic Strategies
Editors: Christiansen, H. (Leipzig);
Christiansen, N.M. (Leipzig)
VIII + 192 p., 16 fig., 5 in color, 6 tab., 2015
List price: CHF 194.00 / EUR 181.00 / USD 228.00
(hard cover)
**Special price: CHF 126.00 / EUR 118.00 /
USD 148.00**
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for
USA and Latin America only
ISBN 978-3-318-05496-5

Pediatric and Adolescent Medicine
Series Editor: Kiess, W. (Leipzig)

Listed in Thomson Reuters indices



Neuroblastoma is a tumor derived from the sympathetic nervous system. It is the most common extracranial solid tumor occurring in children and exhibits a marked variability in outcome when the disease is categorized by clinical (e.g. age or stage) and biologic characteristics. This book gives an introduction into the clinical features of progressive neuroblastoma and focuses on molecular-targeted therapies and immunotherapies of this disease.

It has become increasingly clear that MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) holds a key position in neuroblastoma transformation and gene expression in normal and transformed cells. In the 14 chapters important topics such as genomic alterations in neuroblastoma and strategies for indirect molecular targeting of MYCN are discussed. Two chapters, for example, review apoptotic pathways and proapoptotic molecular targets in neuroblastoma, one focusing on the p53 pathway and the other on the extrinsic and intrinsic pathways of apoptosis. Other chapters cover topics related to immunology in neuroblastoma, such as immune regulation in neuroblastoma, immunotherapy related to passive and active vaccination approaches and additional immunotherapy in the treatment of progressive disease.

This volume is essential reading for all clinicians and basic researchers who are involved in delivering health care to patients with progressive neuroblastoma.

Contents

Preface: **Christiansen, H.; Christiansen, N.M.**

Clinical Introduction

• Clinical Features of Progressive Neuroblastoma: **Simon, T.**

Genomic Alterations

• DNA Copy Number Changes and Beyond: **Fieuw, A.; Schulte, J.H.; De Preter, K.; Speleman, F.**
• Genomic Alterations and Abnormal Cell Cycle in High-Risk Neuroblastoma: **Capasso, M.; Sidarovich, V.; Quattrone, A.; Tonini, G.P.**

Targeting MYCN

• MYCN and MicroRNAs: **Althoff, K.; Schulte, J.H.**
• MYCN and Its Posttranslational Regulation in Neuroblastoma: **Otto, T.**

Apoptosis and Angiogenesis

• Neuroblastoma and the p53 Pathway: **Chen, L.; Tweddle, D.A.**
• Targeting Cell Death Pathways in Neuroblastoma: **Fulda, S.**
• Neuroblastoma and Angiogenesis: **Rössler, J.**

Molecular-Targeted Therapy Studies

• The Role of the Anaplastic Lymphoma Kinase Receptor in Neuroblastoma: **Yeung, C.M.; George, R.E.**
• Molecular-Targeted Therapy in Refractory or Relapsed Neuroblastoma: **Corbacioglu, S.**

Immunology

• Immune Regulation in Neuroblastoma: **Fest, S.; Starke, S.**
• Approaches to Passive and Active Vaccination against Neuroblastoma: **Lode, H.N.**
• Role of Cell Therapy in Neuroblastoma: **Bremm, M.; Brehm, C.; Huenecke, S.; Rettinger, E.; Bader, P.**

Minimal Residual Disease

• Minimal Residual Disease in Neuroblastoma: **Weber, A.**

Author Index / Subject Index

Please use the
promotional code:
DANR16

The easiest way to order: www.karger.com/pamed

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

KARGER

CORPORATE SYMPOSIA



Corporate Symposium 1 – BMS	30
Thursday, May 4, 16:45-18:15 hrs	
Corporate Symposium 2 – Novocure	30
Friday, May 5, 12:30-14:00 hrs	
Corporate Symposium 3 – MSD	31
Friday, May 5, 18:15-19:45 hrs	
Corporate Symposium 4 – MagForce	31
Saturday, May 6, 12:15-13:15 hrs	
Corporate Symposium 5 – Mundipharma	32
Saturday, May 6, 15:15-16:15 hrs	
Corporate Symposium 6 – AbbVie, Inc.	32
Saturday, May 6, 16:30-18:00 hrs	



CORPORATE SYMPOSIA

Corporate Symposium 1 – BMS

**Rethinking glioblastoma:
rational application of immuno-oncology research**

Date: Thursday, May 4
Time: 16:45-18:15 hrs
Room: Gartensaal



Bristol-Myers Squibb

Chair: *Michael Weller, Zurich/CH*

- | | |
|---------------|--|
| 16:45 – 16:55 | Welcome & Introduction
<i>Michael Weller, Zurich/CH</i> |
| 16:55 – 17:15 | Glioblastoma biology and treatment challenges
<i>Michael Weller, Zurich/CH</i> |
| 17:15 – 17:40 | Preclinical rationale for I-O-based treatment strategies
<i>Michael Lim, Baltimore/US</i> |
| 17:40 – 18:05 | Emerging clinical research for I-O in glioblastoma
<i>Wolfgang Wick, Heidelberg/DE</i> |
| 18:05 – 18:15 | Closing, Q & A
<i>Michael Weller, Zurich/CH</i> |

Corporate Symposium 2 – Novocure

Glioblastoma Therapy with Tumor-Treating Fields (Optune®)

Date: Friday, May 5
Time: 12:30-14:00 hrs
Room: Kongresssaal

novocure™

Chair: *Michael Weller, Zurich/CH*
Co-Chair: *Maciej M. Mrugala, Phoenix/US*

- | | |
|---------------|--|
| 12:35 – 12:40 | Welcome & Introduction
<i>Michael Weller, Zurich/CH</i>
<i>Maciej M. Mrugala, Phoenix/US</i> |
| 12:40 – 12:55 | Biological effects of TTFields in glioblastoma
<i>Patrick Roth, Zurich/CH</i> |
| 12:55 – 13:15 | The EF-14 newly diagnosed GBM study in the context of clinical trials:
an overview about the current situation in glioblastoma treatment
<i>David Reardon, Boston/US</i> |
| 13:15 – 13:35 | Optune in daily clinical practice – chances and challenges
US perspective
<i>Maciej M. Mrugala, Phoenix/US</i>
European perspective
<i>Martin Glas, Essen/DE</i> |
| 13:35 – 13:50 | Outlook: TTFields in other indications
<i>Giovanni Luca Ceresoli, Bergamo/IT</i> |
| 13:50 – 14:00 | Q&A / Closing remarks / Take away messages
<i>Michael Weller, Zurich/CH</i> |

CORPORATE SYMPOSIA

Corporate Symposium 3 – MSD

Scientific Symposium Sponsored by MSD

Date: Friday, May 5
Time: 18:15-19:45 hrs
Room: Kongresssaal



Educational Objectives:

- Examine the predictive value of methylguanine-DNA methyltransferase (MGMT) and patient selection with temozolomide
- Introduce neuro-oncologists to immunotherapy
- Review and discuss the rationale and data supporting the potential role of immunotherapy in combination with standard of care (SOC), such as temozolomide

Chair: *Michael Weller, Zurich/CH*

18:15 – 18:20	Welcome & Introduction <i>Michael Weller, Zurich/CH</i>
18:20 – 18:40	Role of MGMT testing: Role in clinical trial design and clinical practice <i>Wolfgang Wick, Heidelberg/DE</i>
18:40 – 19:00	Overview on current immunotherapy efforts in gliomas <i>Michael Weller, Zurich/CH</i>
19:00 – 19:20	How immunotherapy can be best integrated into current standards of care <i>David Reardon, Boston/US</i>
19:20 – 19:40	Q&A Panel Discussion <i>Faculty</i>
19:40 – 18:45	Closing Remarks <i>Michael Weller, Zurich/CH</i>

Corporate Symposium 4 – MagForce

Focal therapy in glioblastoma – current status, what's new?

Date: Saturday, May 6
Time: 12:15-13:15 hrs
Room: Kongresssaal



Chair: *Michael Weller, Zurich/CH*

12:15 – 12:30	Introduction, current state of the art for glioma treatment <i>Michael Weller, Zurich/CH</i>
12:30 – 12:45	Focal therapy in gliomas – latest update <i>Michael A. Vogelbaum, Cleveland/US</i>
12:45 – 13:00	New aspects of thermotherapy in brain tumors – NanoTherm therapy <i>Walter Stummer, Münster/DE</i>
13:00 – 13:15	Discussion <i>Faculty</i>

CORPORATE SYMPOSIA

Corporate Symposium 5 – Mundipharma

Neoplastic meningitis: a new look at a neglected problem

Date: Saturday, May 6

Time: 15:15-16:15 hrs

Room: Kongresssaal



Chair: *Michael Weller, Zurich/CH*

- | | |
|---------------|--|
| 15:15 – 15:20 | Welcome & Introduction
<i>Michael Weller, Zurich/CH</i> |
| 15:20 – 15:35 | Evaluating patients outcome – experience of the German registry
<i>Agnieszka Korfel, Berlin/DE</i> |
| 15:35 – 15:50 | Defining the scope of the problem – learnings of the the NeMeRe registry
<i>Michael Glantz, Hershey/US</i> |
| 15:50 – 16:05 | Should intra-cerebrospinal therapy be a part of treatment in leptomeningeal metastasis from solid tumors?
<i>Emilie Le Rhun, Lille/FR</i> |
| 16:05 – 16:15 | Discussion
<i>Michael Weller, Zurich/CH</i> |

Corporate Symposium 6 – AbbVie, Inc.

Forging new paths in the treatment of glioblastoma

Date: Saturday, May 6

Time: 16:30-18:00 hrs

Room: Kongresssaal




Chair: *Michael Weller, Zurich/CH*

- | | |
|---------------|---|
| 16:30 – 16:35 | Welcome & Introduction
<i>Michael Weller, Zurich/CH</i> |
| 16:35 – 16:55 | Management of glioblastoma: standards of care and future directions
<i>Michael Weller, Zurich/CH</i> |
| 16:55 – 17:15 | Biological significance of EGFR in glioblastoma
<i>Ken Aldape, Toronto/CA</i> |
| 17:15 – 17:35 | EGFR-targeted therapy of glioblastoma: the next 5 years
<i>Martin van den Bent, Rotterdam/NL</i> |
| 17:35 – 17:55 | Panel Discussion and Q&A
<i>Faculty</i> |
| 17:55 – 18:00 | Closing Comments
<i>Michael Weller, Zurich/CH</i> |



www.wfnos.com



NEW APPROACH IN CANCER TREATMENT

NanoTherm[®] Therapy

- Fighting cancer with nanomedicine
- NanoTherm[®] Therapy – a unique approach for focal treatment of solid tumors
- Intra-tumoral application of superparamagnetic nanoparticles and later activation via alternating magnetic field
- European certification for treatment of brain tumors since 2010



INFORMATION



Networking Events	37
General Information	39
Registration Fees	47
Sponsor & Exhibitor Listing	53

Your partner in hemato-oncology

mundi
pharma



NETWORKING EVENTS

Networking Event

Lake Side

Thursday, May 4, 2017

Start: 19:30 hrs

Address: Bellerivestrasse 170, 8008 Zurich

The Welcome Reception will take place at the "Lake Side", a venue approximately 2,2 km distance of the Kongresshaus Zürich. Spend a nice evening with your colleagues while enjoying fingerfood and drinks.

Please note that advance registration is mandatory in order to receive a ticket!

For regular participants:	included in the registration fee
Extra ticket:	EUR 46,- (incl. VAT)
Dress code:	casual

Participation is included in the registration fee but registration for the event is necessary in advance. No sponsoring is used to fund any part of the evening.

Please note that no transportation will be provided by the conference organiser and you will need to make your own way to the "Lake Side".

WFNOS Evening

Uetliberg - Hotel Uto Kulm

Saturday, May 6, 2017

Start: 19:30 hrs

Address: Uto Kulm, 8143 Uetliberg/Zurich

The WFNOS Evening will take place in the Hotel Uto Kulm at the Uetliberg. Enjoy a wonderful evening with seated dinner and an amazing view over the lake area around Zurich.

Please note that seats are limited and advance registration is mandatory in order to receive a ticket!

Regular participants / extra ticket:	EUR 95,- (incl. VAT) per person
Nurse / AHP / PhD Student / Resident / Trainee*:	EUR 50,- (incl. VAT) per person
<i>*only applicable with adequate fee</i>	

Dress code: formal, flat shoes recommended
(10 min walk on an unpaved street from the railway station Uetliberg to the Hotel Uto Kulm)

Please note that no shuttle service will be provided by the conference organiser and you will need to make your own way to the evening venue.

Detailed information can be found on your WFNOS Evening ticket.



05.05.2017
12.35 h

SCIENTIFIC LUNCHTIME SYMPOSIUM

Glioblastoma Therapy with Tumor-Treating Fields (Optune®)




Chair Prof. Dr. Michael Weller
Chairman, Department of Neurology,
University Hospital and University of Zurich



Co-Chair Maciej M. Mrugala, M.D., Ph.D.
Senior Associate Consultant, Neuro-Oncology,
Mayo Clinic Phoenix, AZ, USA

Friday, 5th May 2017, 12.35–14.00h
Kongresssaal (main auditorium)

Long-term survival analysis of EF-14 phase 3 trial



¹ Roger Stupp, Monika E. Hegi, and Ahmed Idbaih, et al on behalf of the EF-14 trial investigators, Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multicenter, phase III trial, 2017 Annual Meeting of the American Association for Cancer Research, April 1-5, 2017; Washington, DC. Abstract AACR CT007

² Roger Stupp, Monika E. Hegi, and Ahmed Idbaih, et al on behalf of the EF-14 trial investigators, Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multicenter, phase III trial, 2017 Annual Meeting of the American Association for Cancer Research, April 1-5, 2017; Washington, DC. Oral presentation AACR CT007

Visit us at our booth to learn more about the Optune® therapy



GENERAL INFORMATION

ACCOMMODATION

The WFNOS Organising Office does not provide housing services.

Official accommodation provider:

Zurich Tourist Service

At the Main Railway Station

8001 Zurich

Tel.: +41 44 215 40 00

Fax: +41 44 215 40 44

E-mail: touristservice@zuerich.com

www.zuerich.com

BADGES

Participants should collect name badges from the conference registration desks. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Lost badges can be replaced at the registration desk. However, a handling fee of EURO 55.- incl. VAT will be charged.

BANK SERVICES - MONEY MATTERS

Banks are generally open weekdays between 9:00 - 16:00 hrs and are closed over the weekend.

There are multiple bank machines (ATMs) open 24 hours a day throughout the city which accept all major international bankcards. The official currency of Switzerland is the Swiss Franc (CHF). Major credit cards are widely accepted, but please always check beforehand.

CAR PARKING

There are 10 park-houses in Zurich City. Signalization boards at traffic hubs show the number of vacant parking places and the way to the park-houses. Alternatively there are parking places with parking meters for short stays (white zone). These are limited from 30 minutes to 2 – 4 hours (with exceptions).

The closest park-houses to the conference venue are the Park-house Bleicherweg and Park-house Park Hyatt.

Park-house Park Hyatt		Park-house Bleicherweg	
Duration	Price	Duration	Price
1 hour	CHF 4,00	1 hour	CHF 4,00
Additional hours	Rising prices per hour	Maximum Daily Fee	CHF 37,00
Maximum Daily Fee	CHF 52,00		
Special Tariffs	Price	Special Tariffs	Price
Night time flat rate 22:00 – 07:00	CHF 2,00	Night time flat rate 21:00 – 06:00 Sundays and public holidays: 1 hour	CHF 1,00 CHF 2,00
Open 24 hours a day, height limit: 3,50 meter		Open 24 hours a day, No elevator, height limit: 2,10 meter	



GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE

Confirmations of attendance with CME credits will be issued after the conference, when filling in the online survey. The organisers will send out an e-mail with a link for the online survey after the conference.

CLIMATE

Zurich has a humid continental climate with warm summers and no dry season. The month of May is characterized by rising daily high temperatures, with daily highs increasing from 17°C to 20°C over the course of the month, exceeding 27°C or dropping below 10°C only one day in ten.

CLOAKROOM AND LUGGAGE

A cloakroom and luggage storage facilities are available in the congress venue next to the Bag Counter. A fee of CHF 3 will be charged per item.

CME CREDITS

The 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.



The 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) is designated for a maximum of (or 'for up to') **20 hours of European external CME credits**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The rules of the EACCME state that participants are kindly asked to give feedback (online evaluation after the meeting).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COFFEE BREAKS

During the morning session breaks, refreshments (coffee, tea and pastry) will be served free of charge to participants wearing name badges in the exhibition area.

CURRENCY

The official currency of Switzerland is the Swiss Franc (CHF).

1 EURO = 1,07 USD = 0,85 GBP = 118,70 JPY = 7,35 CNY = 1,07 CHF (as per date of printing).

DRINKING WATER

The tap water in Zurich is of good quality and can be used without concern.



GENERAL INFORMATION

ELECTRICITY SUPPLY

230 V - 50Hz AC, power plugs of the type J (SEV 1011) or flat power plugs of the type C (CEE7/16).

EMERGENCY SERVICES

European Emergency Number: 112 (Alternatively: Police – 117)

EXHIBITION OPENING HOURS

Thursday, May 4, 2017	09:00 – 18:00 hrs
Friday, May 5, 2017	09:00 – 18:00 hrs
Saturday, May 6, 2017	09:00 – 15:30 hrs

INSURANCE

In registering for the WFNOS 2017 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance.

INTERNET

Internet stations are available in the exhibition area.

WIFI is available in all areas.

The access codes are:

Network: WFNOS2017

Password: wfnos2017

LANGUAGE

The official language of the congress is English (no simultaneous translation).

LUNCH AND REFRESHMENTS

During the lunch breaks, a **light lunch** will be offered free of charge to participants wearing name badges.

MESSAGE BOARD

A message board is available in the exhibition area.



GENERAL INFORMATION

PHARMACIES

Most pharmacies are open during normal trading hours, between 07:30 and 18:30/19:00 hrs between Monday and Friday, until 16:00 hrs on Saturday. They are closed on Sunday. Closest Pharmacies:

Apotheke zur Bleiche, Bleicherweg 46, +41 44 201 17 25

Amavita Apotheke Enge, Tessinerplatz 1, +41 58 851 32 10

TopPharm Apotheke Paradeplatz, Poststrasse 6, +41 44 213 12 30

The pharmacy at the Main Railway Station is open 24 hours, 7 days a week.

POSTERS

Friday, May 5, 17:00-18:00

Poster Session I (Poster Numbers P01.01-P09.28)

Poster mounting:

For posters displayed in Poster Session I, the poster mounting is possible on Friday, May 5, from 08:00-12:30 hrs.

Posters within the Poster Session I will be on display on Friday, May 5 from 17:00-18:00 hrs.

Poster removal:

Friday, May 5 from 18:00-20:15 hrs.

Saturday, May 6, 18:00-19:00

Poster Session II (Poster Numbers P09.29-P19.05)

Poster mounting:

For posters displayed in Poster Session II, the poster mounting is possible on Saturday, May 6, from 08:00-12:15 hrs.

Posters within the Poster Session II will be on display on Saturday, May 6 from 18:00-19:00 hrs.

Poster removal:

Saturday, May 6 from 19:00-19:45 hrs

PREVIEW ROOM

The [Preview Centre](#) is located in the **Room Tagungszentrum 1**.

PROGRAMME CHANGES – ACCESS TO SESSIONS

The conference organisers reserve the right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.



GENERAL INFORMATION

PUBLIC TRANSPORTATION

The Zurich Transport Network (ZVV) is the tariff and transportation network for local public transport in the canton of Zürich and certain neighboring regions. In Zurich City you find a bus or ZVV tram stop at intervals of around 300 meters. At the diverse stops you also view timetable information, the next connections, a zone map and ticket machine. You can purchase tickets for 1 hour or Day Cards for various zones. Zurich City is part of Zone 110, the Airport part of Zone 121. You should always carry tickets with you as tickets are regularly inspected. Online timetable for tram, bus, boat and train: www.zvv.ch/zvv/en/home.html

ZVV Single ticket: CHF 4.40

ZVV Day ticket (24h): CHF 8.80

REGISTRATION DESK OPENING HOURS

Wednesday, May 3, 2017	16:00 – 19:30 hrs
Thursday, May 4, 2017	08:00 – 18:45 hrs
Friday, May 5, 2017	07:30 – 20:00 hrs
Saturday, May 6, 2017	07:30 – 19:15 hrs
Sunday, May 7, 2017	07:45 – 14:15 hrs

SAFETY – CRIME

Zurich can be considered a safe city, when using common sense.

Unfortunately, experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay.
Rather carry a copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag.
If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference center.
- In heavily frequented tourist zones, be aware of attempts of scam and pick pocketing.

SHOPS

Large shops and department stores are open between 09:00 hrs and 20:00 hrs from Monday to Saturday.

All shops, with the exception of small souvenir shops and the shops at the Main Railway Station, are closed on Sunday.

All major credit cards are generally accepted, but it is usually not possible to pay with foreign banknotes.



GENERAL INFORMATION

SITE SEEING IN ZURICH

The most important sights such as the Old Town, Bahnhofstrasse, Grossmünster church and Lake Zurich are all based in Zurich's town centre. They are all reachable within a three-hour walk or can be accessed by public transport. Culture lovers will enjoy a visit to the museum, Opera House, Schauspielhaus (municipal theater) or Tonhalle (concert hall). Nature fans can take a trip to Zurich's very own Uetliberg "mountain", visit the zoo or take a boat to Rapperswil.

SMOKING POLICY

The WFNOS 2017 is officially a "No-smoking-conference".
Note that smoking is banned in public buildings, restaurants and bars.

STAFF

Should you have any questions, the conference staff recognizable by a neon yellow lanyard will be pleased to help you.

TAXIS

In Zurich there are a number of taxi companies for which you can order a taxi by phone.

This usually requires a waiting time of 5 – 10 minutes until the taxi arrives. In the city there are also several taxi stands – at which you can simply seat yourself in the taxi up front. At Zurich's Main Railway Station as well as at Bürkliplatz and Lake Zurich it's generally easy to spot and hail a taxi without much difficulty.

Taxi – starting price	CHF 6,00
Taxi – price per kilometre	CHF 3,80

Taxi Zurich – Tel.: +41 44 666 16 16 or +41 44 444 44 44

TELEPHONE CALLS

The country code of Switzerland is +41 and the area code for Zurich is 44.

GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire beforehand or online at your provider which roaming company in Switzerland offers the cheapest tariffs.

TIPPING

Tips are not obligatory, but they are welcome. The norm is 5-10%, but for smaller bills in cafés and bars it is customary to round up to the nearest whole number.

TOURIST INFORMATION / WELCOME CENTER

At the Main Railway Station
8001 Zurich
Tel.: +41 44 215 40 00
Fax: +41 44 215 40 44
E-mail: touristservice@zuerich.com
www.zuerich.com

Opening hours: Mon - Sat 08:00 – 20:30 hrs, Sun 08:30 – 18:30 hrs



GENERAL INFORMATION

TRAVELLING - GETTING TO ZURICH

By plane:

Zurich Airport has its own train station and you can transfer directly from the plane onto a train.

The trip into the city center takes approximately 10-15 minutes. Single ticket: CHF 6,80.

www.zurich-airport.com

By train:

Zurich's Main Railway Station is the largest and one of the oldest railway stations in Switzerland.

With over 2,900 trains per day, it is also one of the busiest railway stations in the world.

From the railway station, you can walk to the congress venue (approximately 20min) or take the tram.

www.sbb.ch/en/home.html

By bus:

Diverse bus companies offer bus trips to Zurich. With Eurolines, IC Bus or Flixbus you travel relaxed and cheaply from Frankfurt, Munich, Hamburg, Stuttgart, Milan, Turin, Rome, Vienna, Paris, Zagreb, Bratislava, Prague and other cities to Zurich. Buses arrive to Bus-Parkplatz Sihlquai (Ausstellungsstrasse 15, 8005 Zurich).

The Old Town, Main Railway Station, the famous Bahnhofstrasse and the city centre are all within walking distance.

V.A.T.

The VAT rate in Switzerland is 8%.

VENUE

Kongresshaus Zürich

Claridenstrasse 5

8002 Zurich

Switzerland

www.kongresshaus.ch/en/homeen.html

Reference: Zurich Tourism

ZURICH

Zurich unites creative city life and idyllic scenery within the smallest of areas. Art connoisseurs and culture enthusiasts have over 50 museums and more than 100 galleries to choose from, while inquisitive city explorers can discover the striking contrast between the picturesque Old Town and the modern, constantly changing urban quarters. Nature lovers seeking fresh air and green open spaces will delight in the city's location directly by the lake, in its abundant expanses of forest and parkland, and in its very own mountain, the Uetliberg. In addition, the vibrant nightlife, offering the widest choice of entertainment facilities in Switzerland, is perfectly suited to night owls and the young-at-heart.

www.zuerich.com/en

5th quadrennial meeting of the World Federation
of Neuro-Oncology Societies (WFNOS)

abbvie

FORGING NEW PATHS IN THE TREATMENT OF GLIOBLASTOMA

**Kongresssaal, Kongresshaus Zurich,
Saturday May 6, 2017
16:30–18:00**

CHAired BY MICHAEL WELLER,
WHO WILL BE JOINED BY
RENOwNED INTERNATIONAL
EXPERTS MARTIN VAN DEN
BENT AND KEN ALDAPE

This will be an engaging and informative
discussion of current and future approaches
in the management of glioblastoma

Date of Preparation: March 2017
CHVEN170179 03/2017
Copyright © 2017 AbbVie Inc. North Chicago, Illinois, U.S.A.





REGISTRATION FEES

REGISTRATION

Onsite registration is possible during the opening hours of the registration desk as follows:

Wednesday, May 3, 2017	16:00 – 19:30 hrs
Thursday, May 4, 2017	08:00 – 18:45 hrs
Friday, May 5, 2017	07:30 – 20:00 hrs
Saturday, May 6, 2017	07:30 – 19:15 hrs
Sunday, May 7, 2017	07:45 – 14:30 hrs

REGISTRATION FEES

PAYMENT RECEIVED*	REDUCED RATE until January 22	REGULAR RATE from January 23 – March 19	LATE & ON-SITE RATE after March 19
Member EANO/ASNO/SNO or from Member Societies**	EUR 476,-	EUR 550,-	EUR 650,-
Non Member	EUR 755,-	EUR 850,-	EUR 950,-
Nurse / AHP - EANO/ASNO/SNO Member	EUR 160,-	EUR 175,-	EUR 196,-
Nurse / AHP - Non Member	EUR 250,-	EUR 275,-	EUR 305,-
PhD Student/ Resident/Trainee***	EUR 250,-	EUR 275,-	EUR 305,-
WFNOS-EORTC Educational Day	EUR 215,-	EUR 230,-	EUR 250,-
Networking Event	Included in the registration fee (extra ticket EUR 46,-)		
WFNOS Evening	Regular participant & Accompanying ticket	PhD Student/Resident/ Nurse/AHP	
	EUR 95,-	EUR 50,-	

All prices include 8% Swiss VAT. Payments in cash can be processed in EUR or CHF. Payments by credit card/debit card are processed in EUR only.

* Please note that the day of payment is decisive for the registration fee, not the day of registration.

** The registration fee for members also applies to members of any of the Member Societies listed on the following website: www.eano.eu/wfnos/member-societies/. In order to verify your member status please send us an email to wfnos2017@medacad.org at the time of your registration with a **confirmation of payment** of your latest paid membership fee, or an official document proving that you are a member of the respective member society. **Please note that the registration fee for members of ASNO, SNO and Member Societies is not available for onsite registrations. If you want to register with the members' fee make sure you pre-register online.**

*** PhD Students, residents and trainees: Please provide a copy of a Student's ID or a confirmation signed by the head of department **at the moment of your registration** by email to wfnos2017@medacad.org
Confirmations handed in at a later stage cannot be considered.

Please note:

Pre-registration without payment of the registration fee is possible.

The onsite fee will then have to be paid at the registration desk (Credit card or cash in EUR/CHF).

What is covered by the registration fee?

- Admission to all scientific sessions
- Admission to exhibition
- Admission WFNOS Networking Event (free of charge but registration is mandatory!)
- Abstract book and final programme
- Coffee/tea during breaks
- Light lunch

Rethinking Glioblastoma: Rational Application of Immuno-Oncology Research

Thursday, 4 May 2017 | 16:45–18:15

Kongresshaus Zürich

Zürich, Switzerland

Gartensaal Room, Entrance Level

Programme:



Glioblastoma Biology and Treatment Challenges

*Michael Weller, MD
University of Zürich
Zürich, Switzerland*

Meeting Chair



Preclinical Rationale for I-O–Based Treatment Strategies

*Michael Lim, MD
The Johns Hopkins University
Baltimore, MD, United States*



Emerging Clinical Research for I-O in Glioblastoma

*Wolfgang Wick, MD
Heidelberg University Hospital
Heidelberg, Germany*

Full panel discussion to follow presentations

Bristol-Myers Squibb: Official Platinum Sponsor



REGISTRATION FEES

• WFNOS-EORTC Educational Day May 4, 2017

The WFNOS Educational Course is done in collaboration with the EORTC and shares the format of the well perceived EANO/ESMO/EORTC training course. The course will be in English and will feature a series of well-known international experts in the field on all topics relevant for a detailed introduction to or update on Neuro-Oncology. The concept of the course allows all PhD students or residents to get a full insight into modern Neuro-Oncology. You will leave the course in case of full attendance with a WFNOS-EORTC certificate of Proficiency in Neuro-Oncology.

How to register for the Educational Day?

If you wish to attend the Educational Day, please note that it is **NOT** included in the registration fee of the WFNOS 2017 Meeting. The Educational Day is subject to additional registration and costs.

In case you already registered for the WFNOS 2017 Meeting and have now decided to attend the Educational Day additionally, please contact the registration manager.

REGISTRATION FEES (EDUCATIONAL DAY WFNOS-EORTC)

PAYMENT RECEIVED*	REDUCED RATE until January 22	REGULAR RATE from January 23 – March 19	LATE & ON-SITE RATE after March 19
Educational Day WFNOS-EORTC	EUR 215,-	EUR 230,-	EUR 250,-

All prices include 8% Swiss VAT. Payments in cash can be processed in EUR or CHF. Payments by credit card/debit card are processed in EUR only.

* Please note that the day of payment is decisive for the registration fee, not the day of registration.

What is included in the Educational Day fee?

- Admission to courses of your choice
- Syllabus
- Coffee/tea during breaks
- Light Lunch

Scientific Symposium Sponsored by MSD

Friday, 5 May 2017
18:15 – 19:45

Scientific Symposium
Sponsored by MSD

Kongresshaus Zürich
Room: Kongresssaal
Zurich, Switzerland

Chair: Michael Weller (Switzerland)

CHAIR

Michael Weller

Professor, Doctor and Chairman
Department of Neurology
University Hospital Zurich
Zurich, Switzerland

FACULTY

David Reardon

Clinical Director
Center for Neuro-Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Physician and Associate Professor of
Medicine
Harvard Medical School
Cambridge, Massachusetts, USA

Wolfgang Wick

Professor and Chairman
Neurology Clinic and National Center
for Tumor Diseases Heidelberg
Heidelberg University Medical Center
Clinical Cooperation Unit NeuroOncology
German Cancer Research Center
Heidelberg, Germany

Educational Objectives

- Examine the predictive value of methylguanine-DNA methyltransferase (MGMT) and patient selection with temozolomide
- Introduce neuro-oncologists to immunotherapy
- Review and discuss the rationale and data supporting the potential role of immunotherapy in combination with standard of care (SOC), such as temozolomide

AGENDA

18:15 – 18:20	Welcome and Introduction	Michael Weller
18:20 – 18:40	Role of MGMT Testing: Role in Clinical Trial Design and Clinical Practice	Wolfgang Wick
18:40 – 19:00	Overview of Current Immunotherapy Efforts in Gliomas	Michael Weller
19:00 – 19:20	How Immunotherapy Can Be Best Integrated Into Current Standards of Care	David Reardon
19:20 – 19:40	Q&A and Panel Discussion	Faculty
19:40 – 19:45	Closing Remarks	Michael Weller



REGISTRATION FEES

PAYMENT MODALITIES

Payment of registration fees onsite may be made in:

- **Cash**
- **Credit Cards:** Visa and Mastercard

Payments in cash can be processed in EUR or CHF. Payments by credit card/debit card are processed in EUR only.

IMPORTANT

The reduced registration fee is only applicable, if it has been paid to the congress account within the according deadlines. Registering without performing an actual payment will automatically set your balance to the fee applicable onsite.

CANCELLATIONS AND REFUNDS

Notice of cancellation must be made in writing by email or fax to the congress office.

Registration fees may be refunded as follows:

Written cancellation received:

- | | |
|--|------------|
| • before January 22, 2017: | 75% refund |
| • between January 23 and March 19, 2017: | 25% refund |
| • after March 19, 2017: | no refund |

The date of receipt of the email or fax ID will be the basis for considering refunds.

Refunds will be made after the congress to your bank account.

Please see also the General Terms & Conditions (TBA) for participants:

www.eano.eu/wfnos-2017-meeting/terms-and-conditions/

EANO 2019 LYON

SAVE THE DATE

SEPTEMBER 19 - 22, 2019
14TH MEETING & Educational Day

Photo © Laurent Berthier - Caméleon Photographie
ONLYLYON Tourisme et Congrès



www.eano.eu

**EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY**

Centre de Congrès
Lyon, France



SPONSOR & EXHIBITOR LISTING

On behalf of the World Federation of Neuro-Oncology Societies the European Association of Neuro-Oncology gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing).

EXHIBITORS

ABBVIE, INC.
EANO
IBTA
MagForce
MEDAC
Novocure
Orbus Therapeutics
Oxford University Press
Swiss Brain Tumor Foundation
WFNOS 2021



SPONSORS

PLATINUM SPONSORS



GOLD SPONSORS



OTHER SPONSOR





www.wfnos.com



Coordination

WFNOS 2017
c/o WMA Kongress GmbH
Alser Strasse 4 • 1090 Vienna • Austria
t: +43 1 405 13 83 - 27 or 30
f: +43 1 407 82 74
e: wfnos2017@medacad.org
www.wfnos.com

Layout: Barbara Biegl, www.biegl-grafik.at
Photo Credits: Unless otherwise indicated all pictures
© EANO – European Association of Neuro-Oncology

Copyright © 2017 WFNOS
All rights reserved. No part of this publication may be reproduced, distributed or transmitted without the prior written permission of EANO.
Some information may be subject to change.

INTEGRATED TREATMENT. BALANCED RISK. INTRAOPERATIVE CONTROL.

LEARN HOW **ADAPTIVE HYBRID SURGERY** INTEGRATES SURGERY AND RADIOSURGERY FOR TREATMENT OF BENIGN SKULL BASE TUMORS AT [BRAINLAB.COM/AHS](https://www.brainlab.com/AHS).

Meningioma		cf-SRT 30x1.8Gy	hf-SRS 5x4Gy	st-SRS 1x12.5Gy
Volume Coverage (%)	Conformity Index (CI)	● 99% (99%) 1.6 (1.6)	● 99% (99%) 1.5 (1.5)	● 99% (99%) 1.7 (1.4)
Tract, Right		●	●	●
sm		●	●	●
lela, Left		●	●	●
lela, Right		●	●	●
Left		●	●	●
Right		●	●	●
s, Left		●	●	●
s, Right		●	●	●
c Nerve, Left		●	●	●
c Nerve, Right		●	●	●
c Tract, Left		●	●	●
opocampus, Left		●	●	●
opocampus, Right		●	●	●

L

Sagittal View

A

Coronal View

L

EANO 2018 STOCKHOLM

SAVE THE DATE

OCTOBER 11 - 14, 2018
13TH MEETING & Educational Day

Photo © Erik G. Svensson /mediabank.visitsweden.com



www.eano.eu

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

Stockholm Waterfront Congress Centre
Stockholm, Sweden